Valneva, Pfizer Lyme vaccine >70% efficacy in Phase 3 VALOR trial but fails primary endpoint

 Valneva, Pfizer Lyme vaccine PF-07307405 shows >70% efficacy in Phase 3 VALOR trial but fails primary endpoint statistical criterion as Pfizer pursues approval

https://finviz.com/quote.ashx?t=VALN&p=d